Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.41 |
| ▸ | ITGAV | P06756 | 12/20 | 0.39 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 10/20 | 0.39 |
| ▸ | ITGB8 | P26012 | 10/20 | 0.39 |
| ▸ | ITGA8 | P53708 | 10/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834969 | 0.88 | KMT2A (0.37) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL14450496 | 0.87 | PTGDR2 (0.44) | ITGB3ITGA2B | |
| SCHEMBL6779369 | 0.86 | ITGB3 (0.39) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL244261 | 0.84 | ITGB3 (0.50) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL6783154 | 0.83 | ITGB3 (0.52) | ITGB3ITGA2BITGAVGPR139 | |
| SCHEMBL6784179 | 0.83 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL6778078 | 0.81 | ITGB3 (0.45) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL6773611 | 0.80 | ITGB3 (0.46) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL6774572 | 0.79 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB6ITGB1 | |
| SCHEMBL14536297 | 0.79 | ITGB3 (0.44) | ITGB3ITGA2BITGAVITGB6ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | claimed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |